Loading
A Chinese study of about 1,250 people testing a blood test for lung, bowel, liver, stomach and gullet cancer in ordinary screening.
NQMD-CS (NCT07834268) is a single-arm interventional study sponsored by Fifth Affiliated Hospital of Guangzhou Medical University. It evaluates the feasibility of a cell-free DNA methylation test that gives a binary result and predicts tissue of origin for five cancers.
The registry record, read on 29 October 2026, gives its status as active, not recruiting, with 1,250 participants enrolled, a start on 2 July 2025 and primary completion expected in October 2026.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/